Hank C. K. Wuh, MD, MPH – Chairman
Dr. Wuh is the founder and CEO of SKAI Ventures, a global venture accelerator focused on transforming ingenious ideas into disruptive technologies and high growth companies. The motto at SKAI Ventures: Invent. Disrupt. Inspire. A surgeon, inventor, and entrepreneur, Dr. Wuh has led the development of over twenty biomedical and consumer healthcare innovations from concept to commercialization. Dr. Wuh is also the founder ofEyegenix, LLC, which is developing an artificial cornea for transplantation to treat blindness. At the University of Hawaii, Dr. Wuh is a member of the President’s Advisory Council on Innovation and Technology Advancement, Dean’s Council at the School of Engineering, and is Associate Clinical Professor of Surgery at the John A. Burns School of Medicine. Dr. Wuh holds a Bachelor’s degree in Human Biology from Johns Hopkins University, a Masters of Public Health from Harvard University, a Medical Doctorate from Johns Hopkins University School of Medicine, and was Chief Resident in Orthopedic Surgery at Stanford Medical Center.
Michael Bartholomeusz, MS, PhD – Chief Executive Officer
Dr. Bartholomeusz brings more than 20 years of experience leading, building, operating and investing in emerging technology and advanced materials companies. Prior to joining TruTag, he served as CEO and as a member of the Board of Directors for HZO, Inc., a leader in thin film protection from liquids for electronics, overseeing the expansion and development of the company from pre-revenue to high-growth. From 2008 to 2012, Dr. Bartholomeusz served as CEO and co-founder of AQT Solar, a leading producer of thin film solar cell renewable energy products, taking the company from seed-stage to commercialization in less than three years. Dr. Bartholomeusz has extensive experience doing business in Asia where he green-fielded multiple successful joint ventures in China. He has over 25 granted and pending patents and currently sits on the Board of SunEdison Semiconductor (Nasdaq: SEMI) and on the advisory boards of privately-held Cubergand Quantpower. Dr. Bartholomeusz holds a Bachelor’s degree in Physics from the University of California, Santa Cruz, and a M.S. and PhD in Materials Engineering from the University of Virginia.
Gov. George Ariyoshi – Director
The Honorable George Ariyoshi, was a three-term governor of the state of Hawaii and the first Japanese American to become a U.S. Governor. An attorney by profession, he devoted 32 continuous years in public service in the Territorial and State Legislatures, as Lt. Governor and as Governor. He has also served as President of the Bar Association of Hawaii, Chairman of the Western Governor’s Conference, President and Founder of Pacific Basin Development Council, and President and Founding member of Center for International Commercial Dispute Resolution. He is the recipient of six honorary doctorates in law and humanities and is the recipient of Japan’s highest decoration, the Order of Sacred Treasurer, First Class. He has written monthly articles in Hawaii Business Magazine and authored a book, With Obligation to All.
In transitioning himself from politician to citizen, Governor Ariyoshi has served as Chairman of the Board for East-West Center and Pacific International Center for High Technology Research (PICHTR); Member of President Clinton’s Advisory Committee on Trade Policy and Negotiations (ACTPN), the National Public Broadcasting System Board (PBS) and the Japan Foundation Center for Global Policies Board. He was also President of Prince Resorts Hawaii. Governor Ariyoshi remains active as Chairman of the Board of Convergence CT; Director of Accela Inc. and Daily Wellness Company and U.S. Advisor for Japan-U.S. Science, Technology, and Space Applications Program (JUSTSAP) and Honorary Chairman for Northeast Asia Economic Forum (NEAEF).
Gregory S. Leong – Director
Mr. Gregory S. Leong is a Partner and Investment Director at Arocrest Company based in Hong Kong. He has nearly 20 years of corporate finance and strategy experience, primarily focused in private equity investments and management in Asia. Mr. Leong was most recently with the International Finance Corporation (IFC, private sector arm of the World Bank Group) in Singapore as Principal Investment Officer, where he was involved in assessing investment opportunities in agriculture, consumer/retail, infrastructure, energy, TMT, and healthcare industries. Prior to IFC, Mr. Leong was a Managing Director with Blackstone’s Private Equity Group in Hong Kong. At Blackstone, he sourced and executed private equity investments in Greater China and South East Asia as well as cross border/outbound opportunities. He also assisted with fundraising for global and RMB funds and managed relationships with Asian limited partner investors. Prior to Blackstone, he was with H&Q Asia Pacific where he structured private equity investments for growth capital, take private, and leveraged buyout opportunities, and JPMorgan, Hong Kong, in corporate Finance / M&A and Leveraged Finance. Mr. Leong holds an undergraduate business administration degree from George Washington University, a Master of International Public Policy from Johns Hopkins University, and a Master of Business Administration from the University of Chicago.
Ge Li, PhD – Director
Dr. Ge Li is the Founder, Chairman and Chief Executive Officer of WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries. Dr. Li studied at Peking University as an undergraduate and received his Ph.D. in Organic Chemistry from Columbia University. He began his industry career in 1993 as one of the founding scientists at Pharmacopeia, Inc. (NASDAQ: PCOP). In 2000, Dr. Li moved back to Shanghai to found WuXi PharmaTech and has since been its Chairman and CEO. Under Dr. Li’s leadership, WuXi has grown from 4 founders and a single laboratory of 7,000 square feet in Year 2000 to a global operation with over 9,000 employees and facilities totaling 5 million square feet for world-class research, development and manufacturing to help advance some of the most innovative healthcare products for patients around the world. Dr. Li also serves as a board member of Hua Medicine, Adagene, Phagelux, Shanghai Hile Biopharmaceutical Co. Ltd., and serves as an advisory board member of the Shanghai Institute for Advanced Immunochemical Studies (SIAIS) of ShanghaiTech University. Dr. Li’s entrepreneurship and achievements have won him numerous prestigious awards and honors, including “The 25 Most Influential People in Biopharma in 2015”, “Forbes 25 Notable Chinese-Americans”, “The 60 Most Influential People during 60 Years Pharmaceutical Development in China”, “Ernst & Young Entrepreneur of the Year China Award”, “The Boston Biotech Chief Executive Officers Conference Life Achievement Award”, and “The Most Innovative Leader of the Chinese Enterprises”.
Mark Maciejewski – Director
Mark Maciejewski is the founder and managing director of DiNova Venture Partners, a venture capital fund focused on medical devices and life sciences, and he is also the chief executive officer of the DiNova Biomedical Technology Innovation Center located in Shanghai, China. Previously, Mr. Maciejewski was the senior vice president of international investments for the National Technology Enterprise Company of the Kuwait Investment Authority and the managing director of Tyco Ventures/Healthcare. He has been a founder and/or CEO of a number of medical device and biopharmaceutical companies, including Symphony Medical, Inc. and Angioguard, Inc. Mr.Maciejewski currently serves on the boards of Lone Star Heart, Inc. and Broncus Medical, Inc., and he was appointed as co-director of the Cardiac New Technology Innovation Center for FuWai Hospital in Beijing, China and as committee chair for new technology for the Jiading High Technology Innovation Park in Shanghai, China.
Jeffrey Watanabe, Esq. – Director
Jeffrey N. Watanabe is a retired partner of the Honolulu law firm of Watanabe Ing he helped found in 1971. Mr. Watanabe remains active as a business and community leader serving on the boards of Alexander & Baldwin (NYSE: ALEX) and its subsidiary, Matson Navigation Company, First Insurance Company of Hawaii, Grace Pacific Corporation, Oahu Publications (The Honolulu Star-Advertiser and MidWeek), Tissue Genesis and Trex Enterprises. He chairs the board of Hawaiian Electric Industries (NYSE: HE) and is a board member of HEI subsidiaries American Savings Bank and Hawaiian Electric Company. Mr. Watanabe’s work with non-profits includes being a trustee of Sesame Workshop, Punahou School and chairing the Consuelo Foundation headquartered in Honolulu and Manila. He also chairs The Nature Conservancy of Hawaii’s Corporate Council for the Environment.
Barry Weinman – Director
Barry Weinman has been making venture capital investments, principally in Silicon Valley, since 1980. He is Co-Founder and former Managing Director of Allegis Capital and AVI Capital. Mr. Weinman and his partners in Allegis and prior funds have helped over 70 private companies go public. Barry has led and participated in investments resulting in over $25 billion in market value, including: Palm (NASDAQ), Cypress Semiconductor (NYSE), Columbia/HCA (NYSE), Women.com (NASDAQ), Medscape (NASDAQ), Liveworld (NASDAQ), and Quokka Sports (NASDAQ). Prior to becoming a venture capitalist, Mr. Weinman held management positions with AT&T, IBM, and Fairchild Semiconductor. He co-founded Interactive Applications Inc., the first on-line manufacturing software and services company, and merged it with Boole & Babbage which went on to have an Initial Public Offering. Mr. Weinman is a past Chairman of the Board of Trustees of the University of Hawaii Foundation (Endowment) and was the Chair of the University of Hawaii Centennial Campaign, which raised $336 Million against a goal of $250 Million. He is also on the UH President’s Council on Innovation. Mr. Weinman currently serves on the Board of Trustees for The Queen’s Health Systems and for The Queen’s Medical Center in Honolulu, Hawaii.